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A commentary on
Programmable base editing of A·T to G·C in genomic DNA without DNA cleavage
by Gaudelli, N. M., Komor, A. C., Rees, H. A., Packer, M. S., Badran, A. H., Bryson, D. I. et al. (2017).
Nature 551, 464–471. doi: 10.1038/nature24644
An article recently published in Nature (Gaudelli et al., 2017) reports an approach of altering DNA
sequences without cleaving the DNA strands. This method of gene editing, exploits a modified
version of the CRISPR-Cas9 system and an RNA-based deamination enzyme.
INTRODUCTION: GENOME-EDITING BIOTECHNOLOGIES
The clustered regularly interspaced short palindromic repeat (CRISPR) technology is widely used
to mediate genome-editing in a variety of species (Sander and Joung, 2014; Barrangou and Doudna,
2016). CRISPR, a microbial cellular immunity system (Barrangou et al., 2007), allows the precise
editing of DNA sequences and interrogation of regulatory elements, gene function, and protein
networks (Doudna and Charpentier, 2014; Zhang et al., 2014; Amitai and Sorek, 2016). This
function requires the presence of a set of CRISPR-associated (Cas) genes, which usually are
found adjacent to the CRISPR locus. The wild-type Cas9 endonuclease and its different variants
(Jinek et al., 2012; Cong et al., 2013; Qi et al., 2013) have been heavily utilized as the major
component in genome-editing protocols. CRISPR relies on the ability of CRISPR single guide RNAs
(sgRNAs) to target the Cas9 endonuclease to precise genomic locations, where Cas9 introduces
DNA double-strand breaks (Hsu et al., 2013; Doudna and Charpentier, 2014; DSBs). Subsequently,
the cell’s DNA repair machinery mends the DSBs, commonly resulting in random insertions or
deletions (indels) of nucleotides at the location of DSBs (Lieber, 2008).
Several review articles have been published recently on the different classes of customizable
DNA-binding endonucleases that can be exploited to manipulate virtually any genomic sequence
(Cox et al., 2015; Gaj et al., 2016; Yin et al., 2017). Hence, the genome-editing technologies will not
be described in great detail here. Apart from the CRISPR technology (Cong et al., 2013; Mali et al.,
2013), to achieve effective genome-editing by inducing site-specific DNA DSBs three other major
classes of targeted nucleases are currently being exploited: meganucleases (Smith et al., 2006), zinc
finger nucleases (Urnov et al., 2005; Miller et al., 2007), and the transcription activator-like effectors
(Boch et al., 2009;Moscou and Bogdanove, 2009; Christian et al., 2010;Miller et al., 2011). However,
the ease of use and versatility of CRISPR–Cas system has led to its expeditious and wide adoption
for precise modification of DNA sequences.
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BASE EDITING: EXPANDING THE GENOME
ENGINEERING TOOLBOX
At the genomic level, there are two main types of point
mutational changes: nucleotide substitutions and nucleotide
additions or deletions. Although some well-known inherited
genetic disorders are caused by point mutations (Bamshad et al.,
2011; Gilissen et al., 2011; Veltman and Brunner, 2012), current
genome-editing technologies to point mutation correction are
unsuitable. The correction rates of the conventional genome-
editing technologies are 0.1–5%, and typically they induce a
plethora of random indels at the target locus resulting from the
cellular reaction to DSBs (Cox et al., 2015; Hilton and Gersbach,
2015). It has been proposed that these indels might lead to side
effects in therapeutic applications.
When the repair, small alteration or introduction of a point
mutation at a specific genomic site is desired rather than
stochastic disruption of the whole locus, base editing, a novel
genome-editing toolbox offers a more efficient strategy. Base
editing allows the direct, irreversible chemical conversion of
a specific DNA base pair to a different base pair at a target
genomic locus without requiring DSBs, homology directed repair
processes, or donor DNA templates (Komor et al., 2016, 2017;
Nishida et al., 2016). Hence, base editing is an exciting recent
addition to the genome-editing toolbox.
REFINING CRISPR FOR POINT MUTATION
REPAIR
The ACTIVATION INDUCED DEAMINASE (AID)/
APOLIPOPROTEIN B mRNA EDITING ENZYME,
CATALYTIC POLYPEPTIDE-LIKE (APOBEC) family
comprises of proteins with diverse physiological functions.
The family represents a group of cytidine deaminases that
enzymatically deaminate deoxycytidine (C) to deoxyuridine
(U) in single-stranded DNA sequences. AID is one of the
well-studied members of the APOBEC family (Knisbacher et al.,
2016; Salter et al., 2016).
Most of the human pathogenic point mutations have
been attributed to cytosine/guanine (C/G)→ thymine/adenine
(T/A) base pair transitions. Interestingly, Komor et al. (2016)
created several base editors (BEs) that convert C/G→ A/T in
specific-sequence contexts. They achieved this by combining
three polypeptides: (i) a cytidine deaminase; (ii) a mutated
Cas9 CRISPR protein that doesn’t cleave DNA but uses an
associated sgRNA to target specific genomic sequences; and
(iii) a protein that prevents reversion of U→ C. After the
cytidine deaminase changes C→ U, the BE “nicks” the strand
opposite the modification site to induce the cellular apparatus
to replace G→ A and change U→ T. Among the different
APOBEC enzymes exploited, the rAPOBEC1 showed the highest
deaminase activity. Interestingly, the fact that different members
of the AID/APOBEC family have different specificity (Kouno
et al., 2017), this may allow the targeting of different bases.
The recent publication by Gaudelli et al. (2017) describes the
structure and function of a novel base editing tool, the adenine
base editor (ABE). Interestingly, the ABE can accomplish the
opposite function: the A/T→ G/C transition (Gaudelli et al.,
2017). Several generations of ABE have been created (Gaudelli
et al., 2017). The 7th generation of ABE (e.g., ABE7.10) utilizes a
version of the CRISPR-Cas9 system which has the cleavage ability
deactivated (Gaudelli et al., 2017). As a result, ABEs are able
to specifically alter base pairs in the genome without having to
rely on unpredictable repair systems to introduce indels for gene
deactivation, or to splice in new loci.
The development of the ABEs is one of the most exciting
developments in genome-editing technologies. The ABEs are
composed of three main components: an “evolved” version of
transfer RNA adenosine deaminase (TadA), a Cas9 “nickase,” and
a sgRNA (Figure 1; Gaudelli et al., 2017). TadA is the starting
point for ABEs due to their property to convert A→ inosine (I)
in the single-stranded anticodon loop of tRNAArg, which the cells
treat as G (Kim et al., 2006). The same conversion can also be
carried out by the ADENOSINE DEAMINASES THAT ACT ON
RNA (ADARs) enzymes (Zheng et al., 2017). It seems that TadA
was selected as an approach due to the fact that, unlike ADAR,
TadA does not require small-molecule activators (Macbeth et al.,
2005). Natural TadA, however, works only on transfer RNA,
not DNA. To create DNA-modifying versions of TadA, Gaudelli
et al. (2017) generated TadA mutants in Escherichia coli S103041
strain. The E. coli mutant lines were programmed to convert
A→ I in linkage to antibiotic resistance genes in order to survive
the antibiotic challenge. The surviving E. coli encoded TadA
mutations imparted the ability to perform the A→ I conversion
on DNA.
To assemble the ABE, Gaudelli et al. (2017) attached amutated
TadA to a modified form of the Cas9 enzyme. Ordinarily, as part
of a CRISPR/Cas9 gene-editing system, Cas9 cleave DNA, which
is then repaired by one or another set of molecular apparatuses
residing in the cell. However, the mutated “nickase” version of
FIGURE 1 | The Structure of the Adenine Base Editor (ABE). The ABE
contains an atom-rearranging enzyme (in red) that can convert adenine to
inosine (read and copied as guanine), sgRNA (in green), which directs the
molecule to the desired point, and a Cas9 nickase (in blue), which snips the
opposing strand of DNA and tricks the cell into converting the complementary
base (Gaudelli et al., 2017).
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the Cas9 enzyme that has been exploited by Gaudelli et al. (2017)
induces a single-strand DNA break (nick) at a specific point
based on the co-expressed sgRNA-defined target sequence, rather
than a DSB conferred by the native enzyme. Hence, the Cas9
exploited in ABE only nicks DNA at the base opposite the A→ I
conversion site. The “nick” prompts the cell to insert the correct
partner base pair to match the new one, thereby completing
the transition of A/T→ G/C. This specific property of the ABE
has led Gaudelli et al. (2017) referring to ABE as a gene-editing
“pencil,” “overwriting errors” in the genomic sequence, instead of
the “scissors” that CRISPR technology is usually compared to.
Working with samples taken from patients, Gaudelli et al.
(2017) continued the work of Komor et al. (2016), by
exploiting the novel ABE tool to repair a point mutation that
confer hereditary hemochromatosis, a pathological phenotype
characterized by excessive intestinal absorption of dietary iron
that leads to excessive iron uptake and deposition in organs
(Alexander and Kowdley, 2009). In addition, Gaudelli et al.
(2017) exploited the ABE in human cells lines to induce a
mutation that overcomes sickle-cell anemia (Traxler et al., 2016).
Interestingly, in both experimental approaches, they detected
virtually no off-target effects, or indels (typically ≤ 0.1%), which
are a concern with the conventional approaches of implementing
CRISPR to modify whole loci.
CONCLUDING REMARKS
The development of ABEs by Gaudelli et al. (2017) is a
significant addition to the genome-engineering toolbox. BEs use
a component of CRISPR, but they have some advantages over
the standard CRISPR technology. CRISPR is ideal for inserting
and deleting DNA sequences at targeted locations in a genome.
But BEs have the edge for single-base modifications because they
are significantly more efficient than standard CRISPR at making
single-base substitutions. However, BEs are not meant to be a
replacement to conventional genome-editing with CRISPR. But
it is rather an additional tool for modifying the genome in an
attempt to repair flawed genes in cells that cause diseases.
ABEs greatly expand the scope of base editing. Together
with previously described base editors, the work of Gaudelli
et al. (2017) enable the programmable installation of all four
transitions (C→ T, A→ G, T→ C, and G→ A) in genomic
sequences. Hence, ABEs induce point mutations more efficiently
and systematically than a current Cas9 endonuclease-based
biotechnologies, induce less off-target genome edits than
Cas9, and can induce disease-repairing or disease-suppressing
mutations in human genome. Since many genetic diseases arise
from point mutations, BEs such as the ABE, have significant
implications in the elucidation of molecular genetic mechanisms
of cells in health and disease states.
However, more work remains before BEs can be used
to treat patients with genetic diseases. This includes tests
of safety, efficacy, side effects, and advances in methods
to deliver these large biological molecules involved to the
diseased tissues. In addition, the strategies developed and
implemented by Gaudelli et al. (2017) expand the utility and
applicability of BEs. However, additional research is required on
improving the function of sgRNAs to target diverse genomic
sites. Due to the presence of repetitive DNA elements in
the genome and the requirements for specific parameters in
designing sgRNAs, the genomic locations that can be targeted
by exploiting this approach are limited. In addition, the
implemented approach, due to deamination of cytosine, confers
transition mutations. It has been shown that most of the
transition mutations at third position of codons are generally
ineffectual mutations. Hence, the development of a strategy that
confers both transition and transversion mutations could be
beneficial.
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